Skip to main menu Skip to main content Skip to footer


Weight Loss

Semaglutide is a medication that was originally developed for the treatment of type 2 diabetes. However, it has also been studied for its potential effects on weight loss. In some clinical trials, semaglutide has been found to lead to significant weight loss in people with obesity.  Semaglutide belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone that helps regulate insulin secretion, glucose metabolism, and appetite.  All of which can assist in losing those extra unwanted pounds.  

Key Points About Semaglutide and Weight Loss

It’s important to note that while semaglutide may be effective for weight loss, it is not a standalone solution. Hormonal optimization, Lifestyle changes, including a healthy diet and regular physical activity, are typically recommended in conjunction with medication for optimal results.

Appetite Suppression

GLP-1 receptor agonists like semaglutide may help reduce appetite, leading to decreased food intake and subsequent weight loss.

Slowed Gastric Emptying

Semaglutide may slow down the emptying of the stomach, which can contribute to feelings of fullness and reduced calorie intake.

Improved Insulin Sensitivity

By improving insulin sensitivity, semaglutide may help the body use glucose more effectively, potentially leading to weight loss.

Clinical Trials

Semaglutide has been studied in clinical trials specifically for its effects on weight loss. The STEP (Semaglutide Treatment Effect in People with Obesity) program, for example, evaluated the efficacy and safety of semaglutide for weight management.


Yes, semaglutide is FDA-approved for the treatment of type 2 diabetes. It helps lower blood sugar levels by stimulating insulin release and reducing glucagon secretion.

While the exact mechanism is not fully understood, semaglutide is believed to contribute to weight loss by reducing appetite, slowing down gastric emptying, and improving insulin sensitivity. These factors collectively lead to a decrease in calorie intake and improved metabolic function.

Yes, a higher-dose formulation of semaglutide (2.4 mg once weekly) has received FDA approval for chronic weight management in adults with obesity or overweight conditions who have at least one weight-related comorbidity.

The recommended dosage for weight loss is a once-weekly subcutaneous injection of semaglutide at the higher dose of 2.4 mg.

Common side effects may include nausea, vomiting, diarrhea, constipation, and abdominal pain. It’s essential to discuss any side effects with a healthcare provider.

Clinical trials, such as those in the STEP (Semaglutide Treatment Effect in People with Obesity) program, have shown that semaglutide can lead to significant weight loss in individuals with obesity.

Semaglutide is generally prescribed for individuals with obesity or overweight conditions who have at least one weight-related comorbidity. However, its use should be discussed with a healthcare provider, and it may not be suitable for everyone.

Semaglutide may not be suitable for individuals with a history of pancreatitis, severe gastrointestinal disease, or a personal or family history of medullary thyroid carcinoma (MTC). Pregnant or breastfeeding individuals should also avoid its use.

Schedule Your Consultation Today!